Effect of Glyceryl Trinitrate on Hemodynamics in Acute Stroke.
blood pressure
glyceryl trinitrate
heart rate
hemodynamics
hemorrhage
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
11
1
2019
medline:
17
10
2019
entrez:
11
1
2019
Statut:
ppublish
Résumé
Background and Purpose- Increased blood pressure (BP), heart rate, and their derivatives (variability, pulse pressure, rate-pressure product) are associated with poor clinical outcome in acute stroke. We assessed the effects of glyceryl trinitrate (GTN) on hemodynamic parameters and these on outcome in participants in the ENOS trial (Efficacy of Nitric Oxide in Stroke). Methods- Four thousand and eleven patients with acute stroke and raised BP were randomized within 48 hours of onset to transdermal GTN or no GTN for 7 days. Peripheral hemodynamics were measured at baseline (3 measures) and daily (2 measures) during treatment. Between-visit BP variability over days 1 to 7 (as SD) was assessed in quintiles. Functional outcome was assessed as modified Rankin Scale and cognition as telephone mini-mental state examination at day 90. Analyses were adjusted for baseline prognostic variables. Data are mean difference or odds ratios with 95% CI. Results- Increased baseline BP (diastolic, variability), heart rate, and rate-pressure product were each associated with unfavorable functional outcome at day 90. Increased between-visit systolic BP variability was associated with an unfavourable shift in modified Rankin Scale (highest quintile adjusted odds ratio, 1.65; 95% CI, 1.37-1.99), worse cognitive scores (telephone mini-mental state examination: highest quintile adjusted mean difference, -2.03; 95% CI, -2.84 to -1.22), and increased odds of death at day 90 (highest quintile adjusted odds ratio, 1.57; 95% CI, 1.12-2.19). GTN lowered BP and rate-pressure product and increased heart rate at day 1 and reduced between-visit systolic BP variability. Conclusions- Increased between-visit BP variability was associated with poor functional and cognitive outcomes and increased death 90 days after acute stroke. In addition to lowering BP and rate-pressure product, GTN reduced between-visit systolic BP variability. Agents that lower BP variability in acute stroke require further study.
Identifiants
pubmed: 30626285
doi: 10.1161/STROKEAHA.118.023190
pmc: PMC6358219
doi:
Substances chimiques
Nitroglycerin
G59M7S0WS3
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-412Subventions
Organisme : Medical Research Council
ID : G0501797
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/14/4/30972
Pays : United Kingdom
Références
Eur J Neurol. 2016 Dec;23(12):1750-1756
pubmed: 27516056
Stroke. 2013 Nov;44(11):3120-8
pubmed: 24003041
Int J Cardiol. 2017 Sep 15;243:466-470
pubmed: 28747037
Lancet Neurol. 2009 Oct;8(10):938-48
pubmed: 19747655
J Hypertens. 2006 Jul;24(7):1413-7
pubmed: 16794492
Heart. 2015 Apr;101(8):616-22
pubmed: 25480883
Stroke. 2012 Mar;43(3):857-9
pubmed: 22156691
JAMA. 2014 Feb 5;311(5):479-89
pubmed: 24240777
Int J Stroke. 2014 Aug;9(6):711-20
pubmed: 25043647
Lancet Neurol. 2014 Apr;13(4):364-73
pubmed: 24530176
Stroke. 2011 Feb;42(2):491-3
pubmed: 21183747
N Engl J Med. 2016 Sep 15;375(11):1033-43
pubmed: 27276234
Lancet. 2011 Feb 26;377(9767):741-50
pubmed: 21316752
Lancet. 1992 Mar 21;339(8795):721-4
pubmed: 1347591
Stroke. 2015 Dec;46(12):3362-9
pubmed: 26486868
Blood Press Monit. 1996 Feb;1(1):55-61
pubmed: 10226203
Int J Stroke. 2006 Nov;1(4):245-9
pubmed: 18706028
N Engl J Med. 2013 Jun 20;368(25):2355-65
pubmed: 23713578
Int J Stroke. 2019 Feb;14(2):191-206
pubmed: 28762896
Stroke. 2015 Nov;46(11):3194-201
pubmed: 26463698
Curr Neurovasc Res. 2018;15(1):34-38
pubmed: 29577862
Lancet. 2010 Mar 13;375(9718):906-15
pubmed: 20226989
Cerebrovasc Dis. 2001;11(3):265-72
pubmed: 11306778
J Stroke Cerebrovasc Dis. 2003 May-Jun;12(3):143-51
pubmed: 17903919
Stroke. 2016 Jun;47(6):1479-85
pubmed: 27165954
Lancet Neurol. 2010 May;9(5):469-80
pubmed: 20227347
Hypertension. 2004 Jan;43(1):18-24
pubmed: 14662649
Stroke. 2009 Jun;40(6):2098-103
pubmed: 19359649
CNS Drugs. 2017 Jan;31(1):1-9
pubmed: 27873224
Stroke. 2015 Sep;46(9):2482-90
pubmed: 26243226
Stroke. 2011 Dec;42(12):3511-7
pubmed: 21960578
Int J Stroke. 2014 Apr;9(3):372-4
pubmed: 24588789
J Intern Med. 2004 Feb;255(2):257-65
pubmed: 14746563
Hypertension. 2006 Jun;47(6):1209-15
pubmed: 16682611
Int J Stroke. 2015 Feb;10(2):224-30
pubmed: 25427291
Lancet. 2015 Feb 14;385(9968):617-628
pubmed: 25465108
Stroke. 2018 Feb;49(2):348-354
pubmed: 29301973